Latest News

New Vertex cystic fibrosis drug approved, extending treatments to 90% of patients

Vertex Pharmaceuticals on Monday won approval for its fourth treatment for cystic fibrosis, a combination drug that extends a new form of therapy to 90% of CF patients.

The drug will be marketed as Trikafta. The list price is $311,000 per year — the same as one of Vertex’s earlier CF treatments.

Read the rest…

Source link

Related posts

Change Healthcare Inc. Announces Updated Fireside Chat Time at the Barclays Global Healthcare Conference 2020


Is a Haywire Body Clock Tied to Mood Disorders?


Today In Medical History – February 9


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy